Foghorn Therapeutics Inc. (FHTX) Stock Analysis

Company Overview

Foghorn Therapeutics Inc. (FHTX) carries a market capitalisation of $292.18M. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 106 employees.

The most recent close on file for FHTX is $4.92, dated September 4, 2026. That is +$0.05 (+1.03%) against the previous close. The 52-week range on file runs from $3.27 to $7.61. The latest close sits 50.46% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $30.91M. That is +36.75% against the prior fiscal year, when revenue was $22.60M. The same year closed with a net loss of $74.28M. Profit margin runs at −175.78%. That is 175.8 percentage points below the Biotechnology median of 0%. Earnings per share on a trailing basis come to −1.

Across the 4 fiscal years on file, revenue moves from $19.23M in 2022 to $30.91M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 7.95 times revenue. On price-to-sales that is 47.9% below the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

The reported beta is 2.86. Daily returns over the trailing 5 years annualize to a volatility of 92.89%. The trailing one-year price return is −8.72%. Measured over 5 years, that is −18.50% a year compounded.

Growth & Income

The record shows no dividend for FHTX.

Across the complete calendar years on file, 2025 returned +14.41% and 2022 returned −72.10%. Of the 5 complete calendar years on file, 3 finished higher. 2026 is still running; the price is −8.89% year to date.